FDA proposes to remove low blood pressure drug from market
The Food and Drug Administration (FDA) wants to withdraw its approval of midodrine hydrochloride, a medication used to treat the low blood pressure condition orthostatic hypotension, because post-approval studies that verify the clinical benefit of the drug have not been done. This is the first time the agency has issued a withdraw proposal for a drug approved under the FDA’s accelerated approval regulations.
![[ Beasley Allen Law Firm Logo ]](http://www.southerninjurylawyer.com/wp-content/themes/system-unity/images/logo.png)


The Food and Drug Administration (FDA) is warning health care professionals and patients about the potential for developing a type of pneumonia when treated with Cubicin (daptomycin), an intravenous antibacterial drug used to treat MRSA and MSSA, serious difficult-to-treat staph infections of the skin and bloodstream. Eosinophilic pneumonia is a rare but serious condition where a type of white blood cell (eosinophil) fills the lungs. Symptoms include fever, cough, shortness of breath, and difficulty breathing. If not quickly recognized and appropriately managed, esoinophilic pneumonia may lead to progressive respiratory failure and death.
The U.S. Consumer Product
The suffocation death of a 4-month-old baby who was using a portable baby recliner in a crib has spurred the Consumer Product
Another 21 lots of Tylenol, Motrin and Benadryl are being added to a
The herbal weight loss supplement Que She, advertised as “Slimming Factor Capsule” and as “an all-natural blend of Chinese herbs,” widely distributed on Internet sites such as the Bouncing Bear Botanicals website and at retail outlets such as Sacred Journey in Lawrence, Kansas, has been found to contain ingredients that can cause serious harm to consumers, according to an analysis conducted by the Food and Drug Administration (FDA).
The Consumer Product 